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1. Introduction 
Advances in synthetic arbohydrate chemistry 
have resulted in the chemical synthesis of oligo- 
saccharide chains related to the precursors of the 
major blood group antigens, and such synthetic 
oligosaccharides were recently shown to be of value 
in defining the specificities of anti-1 antibodies [ 1,2]. 
The synthetic oligosaccharides: 
Ga431+4GlcNAcpl+6Gal (oligosaccharide 4) 
and 
Gal(31+3GlcNAc@ L 
3Gal 
I6 
(oligosaccharide 2) 
Ga@1+4GlcNAcPl 
were shown to be indistinguishable from authentic 
oligosaccharides containing the unsubstituted sequence 
Galpl+4GlcNAc&l+6Gal in their inhibitory activities 
with the anti-1 antibody of patient Ma [ 11. Radio- 
immunoassays with 10 other anti-1 sera showed that a 
second anti-1 antibody (from patient Woj) was also 
inhibited by oligosaccharides 2 and 4. None of the 
anti-1 sera were inhibited by the synthetic oligo- 
saccharide analogues: 
Galfil+3GlcNAc/31+3Gal (o igosaccharide 3)
Gal/31+3GlcNAc/31+6Gal (oligosaccharide 5)
Abbreviations: Gal, Dgalactopyranose; GlcNAc, Z-acetamido 
2deoxy-Dglucopyranose; Cer, ceramide 
* To whom correspondence should be addressed 
ElsevierfNorth-Holland Biomedical Press 
at 
and 
GlcNAc@ 1L 
3Gal (oligosaccharide 1)
GlcNAcP 1 
r6 
the highest levels tested (108-l 82 nmol). In the 
present studies the I and i activities of additional 
synthetic oligosaccharides: 
3Gal (oligosaccharide 6) 
GlcNAcP 1 
P 
Ga@l+4GlcNAc/31+3Gal (oligosaccharide 7) 
Gal/31+4GlcNAc$?lL_ 
3Gal (oligosaccharide 8) 
Galpl+4GlcNAc/3 1 
P 
Gal/31+4GlcNAc (oligosaccharide 9) 
and Gal@ 1+3GlcNAc (oligosaccharide 10) have been 
determined by radioimmunoassays nd it has been 
shown that oligosaccharides containing the sequence 
GaQ31+4GlcNAc/31+3Gal haveinhibitory activity 
toward the majority of anti-1 (other than Ma and 
Woj) and anti-i antibodies. However, the amounts of 
these 1+4,1+3 linked oligosaccharides required to 
demonstrate inhibition were 50-lOO-times greater, 
on a molar basis, than the amounts of l-+4,1+6 
linked oligosaccharides required with anti-1 Ma and 
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Woj. These obse~ations support earlier suggestions 
[3] that for optimal reactivity the binding sites of 
the former antibodies require additional antigenic 
determinants on longer oligosaccharide chains. 
2. Materials and methods 
2.1. Anti-I and anti-i sera 
Six anti-1 sera (Ma, Woj, Step, Da, Ver, Zg) and 
three anti-i sera (McC, Tho, Den) were studied; they 
were all obtained from patients with chronic cold 
agglutinin syndrome and have been described [ 1,3-61. 
2.2. Oligosaccharides 
The oligosaccharides used as inhibitors of the anti-1 
and anti-i sera in radioimmunoassays reshown in 
table 1. ~ligo~~~h~des l-9 were prepared by 
chemical synthesis f7-101 in the laboratory of 
Professor S. David. Oligosaccharide 10 and lactose (L) 
were purchased, respectively, from Sefochemical Fine 
Chemicals Ltd., Israel, and Sigma London Chemical 
Co., England. The numerical designation for the 
synthetic oligosaccharides was empirical: designations 
1-5 were used as in [ 11. 
2.3. Radioinmunoassays 
The inhibitory activities of the oligosaccharides 
with the anti-1 and anti-i sera were evaluated by a 
double antibody radio~munoas~y as in [ 1 ,l l]. The 
results were expressed as nmol oligosaccharides 
required to give 50% inhibition of binding of the 
antisera to 12SI-labelled blood group I or Ii active 
glycoproteins. Table 1 shows the maximum amount 
of each oligo~c~haride t sted in the present and the 
previous [I] studies. 
3. Results and discussion 
The specificity of the anti-1 antibodies Ma and Woj 
for the sequence Ga@l+4GlcNAc~l_dGal was further 
substantiated, for oligosaccharide 8 resembled oligo- 
saccharides 2 and 4 in giving 50% inhibition of binding 
at 12 and 16 nmol, respectively, with these two 
antisera (fig.1). Oligosaccharides 7 and 9 which 
contain only a part of this sequence (G~l~GlcNA~) 
were considerably less active and 100-500 nmol were 
mo 
so 
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Fig.1 Inhrbition of biding of 6 anti-1 and 2 anti-i sera to 
**%labelled blood group I-active or Ii-active glycoproteins by 
synthetic oligosaccharide. Symbols: l-10 and L refer to 
oligosaccharides a defied in table 1. A third anti-i serum 
Den showed no inhibition with oligosaccharides l-7 and 9 
at the levels indicated in table 1 and is not illustrated. For 
completeness the radio~munoas~y data from an earlier 
study f 1 ] are also included. 
137 
T
a
b
le
 2
 
C
o
m
p
a
ri
so
n
 o
f 
th
e
 a
m
o
u
n
ts
 o
f 
fr
e
e
 o
llg
o
sa
cc
h
a
ri
d
e
s a
n
d
 g
ly
co
lip
id
s i
n
se
rt
e
d
 ln
 c
h
o
le
st
e
ro
l/
le
ci
th
in
 lip
o
so
m
e
s r
e
q
u
ir
e
d
 to
 g
iv
e
 in
h
ib
it
io
n
 w
it
h
 a
n
ti
-1
 
a
n
d
 a
n
ti
-i
 s
e
ra
 in
 r
a
d
io
im
m
u
n
o
a
ss
a
y
s 
In
h
ib
it
o
rs
 
A
n
ti
-I
 
A
n
ti
-i
 
M
a
 
W
o
j 
S
te
p
 
D
a
 
V
e
x 
Z
g
 
M
cC
 
T
h
o
 
n
m
o
l g
iv
in
g
 5
0
%
 in
h
ib
it
io
n
 
G
a
l@
1
4
G
lc
N
A
c 
(o
llg
o
sa
cc
h
a
ri
d
e
 
9
) 
G
~
l4
G
lc
N
A
~
l~
G
~
 
(o
~
o
~
cc
h
~
d
e
 4
) 
G
a
l@
l4
G
lc
N
A
c@
l-
*3
G
a
l (
o
lig
o
sa
cc
h
a
ri
d
e
 
7
) 
G
a
1
8
1
4
G
lc
N
A
c~
lL
 6
 
G
a
l,
$
1
4
G
lc
N
A
c#
l , 
3
G
a
l (
o
lig
o
sa
cc
h
ti
d
e
 8
) 
G
a
l&
1
4
G
lc
N
A
c/
3
l+
6
G
a
l@
1
4
G
lc
N
A
cp
1
-+
3
G
a
@
1
4
G
lc
@
+
C
e
r 
(s
tr
u
ct
u
re
 V
Ig
d
 
G
~
l4
G
lc
N
A
~
l~
3
G
~
l4
G
lc
N
A
c~
I~
3
G
~
l4
G
lc
~
e
~
 
(s
tr
u
ct
u
re
 V
iII
)d
 
G
a
l@
l4
G
lc
N
A
@
l 
‘6
 
G
a
lJ3
1
4
G
lc
N
A
c~
l’
 3
G
a
l@
1
4
G
lc
N
A
cp
l-
+
3
G
a
l@
1
4
G
lc
@
-+
C
e
r 
(s
tr
u
ct
u
re
 IIg
d
 
~
_ 
- 
lo
o
 
5
0
0
 
2
4
0
0
 
-a
 
(l
o
%
)b
 
(1
0
%
) 
- 
- 
=
3
2
0
0
c 
~
4
0
0
0
 
1
2
 
1
6
 
- 
(1
2
%
) 
(1
0
%
) 
Il.
t.
f 
- 
- 
5
0
0
 
5
0
0
 
1
0
0
0
 
7
0
0
 
1
0
0
0
 
1
2
0
0
 
8
0
0
 
1
6
0
0
 
1
2
 
1
6
 
6
0
0
 
7
0
0
 
(3
0
%
) 
n
.t
. 
(3
0
%
) 
- 
=
2
0
0
0
 
=
2
0
0
0
 
0
.1
 
0
.2
 
-e
 
- 
- 
- 
- 
- 
- 
- 
0
.3
 
- 
0
.0
3
 
- 
0
.0
8
 
0
.0
2
 
0
.2
 
0
.2
 
0
.0
2
 
0
.0
5
 
0
.0
3
 
- 
- 
- 
a
 W
it
h
 th
e
 o
lig
o
sa
cc
h
a
ri
d
e
s;
 
- 
=
 n
o
 in
h
ib
it
io
n
 d
e
te
ct
e
d
 a
t 1
0
0
0
 n
m
o
l 
b
 T
h
e
 fi
g
u
re
 in
 p
a
re
n
th
e
se
s in
d
ic
a
te
 %
 ~
ib
it
io
n
 
a
t 
1
0
0
0
 n
m
 
c 
T
h
e
 fi
g
u
re
s p
re
ce
d
e
d
 b
y 
=
 a
re
 a
n
 e
st
im
a
te
 o
f 
n
m
o
l o
llg
o
sa
cc
h
a
ri
d
e
 
re
q
u
ir
e
d
 fo
r 
5
0
%
 in
h
ib
it
io
n
 o
b
ta
in
e
d
 b
y 
re
a
so
n
a
b
le
 e
x
tr
a
p
o
la
ti
o
n
 
d
 T
h
e
 d
a
ta
 sh
o
w
n
 fo
r 
th
e
 g
ly
co
sp
h
in
g
o
lip
id
 st
ru
ct
u
re
s II
I,
 V
II 
a
n
d
 V
III
 
a
re
 d
e
ri
ve
d
 fr
o
m
 [
 4
,5
] 
e
 W
it
h
 th
e
 g
ly
co
sp
h
ln
g
o
lip
id
s;
 - 
=
 n
o
 in
h
ib
it
io
n
 a
t 0
.3
 n
m
o
l 
f 
n
.t
.,
 n
o
t t
e
st
e
d
 
Volume 104, number 1 FEBS LETTERS August 1979 
required for 50% inhibition. Oligosaccharides 1,3,5 
and 10 which lacked this sequence were not active. 
Inhibition of the anti-1 sera Step, Da, Ver, Zg and 
the anti-i sera McC and Tho was obtained with 
oligosaccharides ‘7 or 8 which contain the sequence 
Galpl+4GlcNAc~l-+3Gal. The reactivity of the anti-i 
antibody McC with the milk oligosaccharide la&o-N- 
neotetraose which contains the 1+4,1+3 sequence 
has been reported [6]. However, the amounts of these 
oligosaccharides required to give 50% inhibition were 
very high, ranging from 600 to - 2000 nmol (fig.1, 
table 2). In agreement with previous inhibition data 
with purified glycosphingolipids erived from erythro- 
cytes [4,5], oligosaccharide 8 (containing the 1+4, 
1+3 sequence as part of a branched structure) was 
more active than the straight chain oligosaccharide 
7 with anti-1 Step, and only the latter oligosaccharide 
was active with anti-i Tho. However, with anti-1 Da, 
the two oligosaccha~des were equally active, and 
with anti-1 Ver and anti-i McC oligosaccharide 7 was 
slightly more active than 8. In exploratory experiments 
with anti-i Den, no inhibition was observed (table 1, 
fig.1); this antiserum was not investigated further. 
In table 2 a comparison is made of the amounts of 
oligosaccharides 4,7,8 and 9 required in the present 
studies and the amounts of the purified I and i active 
~ycosp~ngolipids, structures III, VII and VIII [4,5], 
that were previously required to inhibit these antisera. 
Since the glycosphingolipids were assayed after 
polyme~zation on cholesterol~eci~ liposomes, far 
smaller amounts of them were required (0.02-0.3 nmol) 
than the oligosaccharides to give 50% inhibition of 
binding (these amounts, 20-300 ng inhibitor, are 
comparable to the amounts of Ii-active complex 
glycoproteins usually required to give comparable 
inhibition [ 1,5]). In contrast o the requirements 
with the oligosaccharides in the present studies, the 
amounts of the ~ycosp~ngolipid st~ctures III and/or 
VIII required to inhibit anti-1 sera Step, Da and Ver 
and anti-i McC and Tho were not greater than the 
amounts of structures III or VII that were required 
to inhibit Ma and Woj. In fact the mounts of structure 
VIII required with the anti-i sera McC and Tho were 
substantially smaller. These latter antisera may 
require 50-loo-fold greater amounts of oligo- 
saccharides 7 and 8 because these oligosaccharides 
represent only a part of the antigenic determinants 
they recognize. These observations are in support of 
previous uggestions that the antigens recognized by 
anti-i antibodies involve oligosaccharide chains with a 
repeating Galpl-t4GlcNAc#l+3 sequence [3]. 
It is of interest hat oligosa~charides 1,2 and 7 
were equally active as inhibitors of anti-1 Step, 
suggesting that the -GlcNAc@l+3Gal- component of 
the G~l~GlcNAc~l~3Gal~quen~ contains 
important antigenic determinants reactive with the 
combining site of this antibody. The glycosphingolipid 
GlcN AC/~ 1 
P3 
4GlcNAc~l+3Gal@+4Glc&tCer fstructure IV) 
was previously shown to be inhibitory with this 
antise~m at -0.3 nmol f4]. However, its analogue, 
devoid of the terminal galactose: 
GlcNAcSl. 
. L 
d;GW+ 
GlcNAca 1’ 
4Gl~NAc~l~3G~l~Gl~~~er (structure VI) 
was not active at 0.3 nmol. It is tempting to speculate 
that this discrepancy may be due to a difference in 
the conformation of a free oligosaccharide ascom- 
pared with the same sequence on a glycosphingolipid 
inserted into a liposome. However, it would be 
necessary to test the ~y~osp~gohpids at levels 
> 0.3 nmol to confirm their lack of activity. 
The significance of the weak inhibitions given by 
certain of the oligosaccharides at levels > 1000 nmol 
(fig.1) is uncertain. The total lack of i~ibition with 
other oligosaccharides at this level suggests hat the 
weak inhibitions observed may be due to a partial 
recognition of these structures. 
Since anti-1 Zg differed from 10 other anti-1 
antibodies in not being inhibited (at the highest dose 
tested, 0.3 nmol) by the glycosphingolipid structures 
III, VII or VIII which contain branched or straight 
‘type 2’ o~go~~ch~de chains with terminal 
Galpl-t4GlcNAc sequence ([ 5 J, table 2), it was of 
interest o evaluate its reactivity with ‘type 1’ 
139 
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oligosaccha~de chains with terminal Ga&31+3GaI 
sequence. Limited amounts of oligosaccharides were 
available for testing with this antiserum (table 1, 
fig.1). However, there wasno evidence for preferential 
reactivity with ‘type 1’ chains; on the contrary, 
oligosaccharide 7 with l-*4, l-t3 sequence, was a 
considerably better inhibitor than oligosaccharide 6 
which contains the l-+3, I+3 sequence. 
From these data it can be anticipated that antigenic 
analysis with longer synthetic oligosaccharide 
analogues will contribute substantially to the defini- 
tion of the antigenic dete~in~ts recognized by 
various monoclonal anti-1 and anti-i antibodies for 
they will provide opportunities to investigate the 
antigenic roles of internal residues on blood group 
precursor chains. Thus they will usefulIy suppIement 
the information already available from purified 
glycosphingolipids of erythrocytes. 
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